We observed a 18% reduction in the risk of hospitalization due to HF among patients with baseline CVD (n = 28,085 in each exposure group) comparing DPP-4 inhibitors to GLP-1 agonists users (HR, 0.82; 95% CI 0.77, 0.86). This evidence concerns the gene DPP4 and hydrops fetalis.